Experienced clinical team provides ongoing training and support
Led by a nationally respected oncology nurse, the DigniCap clinical support team is available to patients and clinicians by phone, online, app, and in person. 

Superior results in the pivotal trial for FDA clearance
DigniCap achieved 66.3% success with taxanes in the U.S. clinical trial vs the competitor’s success rate of 59% with taxanes and 50.5% overall.

Longer clinical trial treatment evaluation period
More hair loss will occur with a greater number of treatments. For accuracy, success must be measured at end of treatment. In the clinical trial DigniCap was evaluated one month after the end of all the patient’s chemotherapy cycles, whereas the competitor’s trial was evaluated after just four chemotherapy sessions. 

Wide range of cap sizes
DigniCap is available in four sizes to fit a wide range of head shapes and sizes.

Extensive experience in the U.S. market
In 2015, DigniCap became the first scalp cooling device to receive FDA clearance. Expanded clinical indications from the FDA After an extensive review of worldwide studies, in 2017 the FDA expanded the clinical indication for DigniCap to include men and women with solid tumor cancers.

In-cap sensors for superior temperature control and safety
DigniCap is the only scalp cooling system with patented dual sensors in the cooling compartments for consistent cooling and temperature management, plus a built-in safety sensor to ensure scalp temperature always stays above 32°F / 0°C. 

Marketing services with extensive media attention
Proactive promotion of your institution, clinicians, and patient stories to consumer and healthcare media.

For more information on clinically superior scalp cooling with DigniCap click HERE.

The DigniCap Scalp Cooling System incorporates a number of features and technological advances that combine to improve the patient experience.











  1. The DigniCap Scalp Cooling System has two dedicated temperature regulation sensors in each cap to monitor scalp temperature, and a third safety sensor to ensure that the temperature on the scalp always remains above 32° F/0° C.
  2. Manual gel caps must be refitted every 20 minutes throughout treatment. DigniCap is fitted once at the start of treatment and remains on until completion.
  3. Since manual gel caps warm up during use, each cap must be at approximately -31° F/-35°C at time of fitting. DigniCap is cooled down gradually from room temperature for patient comfort. The safety sensors in the DigniCap ensure that the scalp cooling temperature never falls below 32° F/0°C.
  4. Manual gel cap patients must typically acquire and return caps from a third-party supplier and have a capping assistant present throughout each treatment.
Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 877-350-2150

Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy